Division of Nuclear Medicine, Stanford Hospitals & Clinics, 300 Pasteur Dr, Room H-0101, Stanford, CA 94305, USA.
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1952-9. doi: 10.1007/s00259-009-1206-x.
Only a limited number of studies have evaluated the efficacy of 18F-FDG PET/CT for recurrent cervical carcinoma, which this study seeks to expand upon.
This is a retrospective study of 30 women with cervical carcinoma who had a surveillance PET/CT after initial therapy. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated using a 2 × 2 contingency table with pathology results (76%) or clinical follow-up (24%) as the gold standard. The Wilson score method was used to perform 95% confidence interval estimations.
The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for the detection of local recurrence at the primary site were 93, 93, 93, 86, and 96%, respectively. The same values for the detection of distant metastases were 96, 95, 95, 96, and 95%, respectively. Seventy-one percent of the scans performed in symptomatic patients showed true-positive findings. In comparison, 44% of scans performed in asymptomatic patients showed true-positive findings. But, all patients subsequently had a change in their management based on the PET/CT findings such that the effect was notable. The maximum standardized uptake value ranged from 5 to 28 (average: 13 ± 7) in the primary site and 3 to 23 (average: 8 ± 4) in metastases which were significantly different (p = 0.04).
This study demonstrates favorable efficacy of 18F-FDG PET/CT for identification of residual/recurrent cervical cancer, as well as for localization of distant metastases.
仅有少数研究评估了 18F-FDG PET/CT 对复发性宫颈癌的疗效,本研究旨在对此进行扩展。
这是一项回顾性研究,纳入了 30 例初始治疗后进行监测性 PET/CT 的宫颈癌女性患者。使用以病理结果(76%)或临床随访(24%)为金标准的 2×2 列联表计算敏感性、特异性、准确性、阳性预测值和阴性预测值。采用 Wilson 评分法进行 95%置信区间估计。
PET/CT 对原发部位局部复发的检测敏感性、特异性、准确性、阳性预测值和阴性预测值分别为 93%、93%、93%、86%和 96%,对远处转移的检测敏感性、特异性、准确性、阳性预测值和阴性预测值分别为 96%、95%、95%、96%和 95%。在有症状患者中,71%的扫描显示为真阳性结果,而在无症状患者中,44%的扫描显示为真阳性结果。但所有患者随后都根据 PET/CT 结果改变了治疗方案,效果显著。原发部位的最大标准化摄取值范围为 5 至 28(平均 13±7),转移部位为 3 至 23(平均 8±4),两者差异有统计学意义(p=0.04)。
本研究表明 18F-FDG PET/CT 对识别宫颈癌残留/复发以及定位远处转移具有良好的疗效。